{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:33:34Z","timestamp":1794018814393,"version":"4.8.0"},"reference-count":27,"publisher":"American Chemical Society (ACS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/na","name":"CARB-X","doi-asserted-by":"publisher","award":["IDSEP160030"],"award-info":[{"award-number":["IDSEP160030"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multi-drug-resistant Enterobacteriales expressing a wide array of \u03b2-lactamases are emerging as a global health threat in both hospitals and communities. Although several intravenous drugs have recently been approved to address this need, there are no oral Gram-negative agents that are both safe and broadly effective against such pathogens. The lack of an effective oral agent is of concern for common infections which could otherwise be treated in the community but, due to antibiotic resistance, require hospitalization to allow for intravenous therapy. ETX1317 is a novel, broad spectrum, serine \u03b2-lactamase inhibitor of the diazabicyclooctane class that restores the antibacterial activity of multiple \u03b2-lactams against multiple species of multi-drug-resistant Enterobacteriales, including carbapenem-resistant strains. A combination of its oral prodrug, ETX0282, and the oral prodrug of a third-generation cephalosporin, cefpodoxime proxetil, is currently in clinical development. This report describes the biochemical and microbiological properties of ETX1317, which is more potent and demonstrates a greater breadth of inhibition than avibactam, the parenteral prototype of this class of \u03b2-lactamase inhibitors.<\/jats:p>","DOI":"10.1021\/acsinfecdis.0c00020","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T14:14:15Z","timestamp":1586268855000},"page":"1389-1397","source":"Crossref","is-referenced-by-count":34,"title":["<i>In Vitro<\/i>\n                    Characterization of ETX1317,\na Broad-Spectrum \u03b2-Lactamase Inhibitor That Restores\nand Enhances \u03b2-Lactam Activity against Multi-Drug-Resistant\n                    <i>Enterobacteriales<\/i>\n                    , Including Carbapenem-Resistant Strains"],"prefix":"10.1021","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7110-0493","authenticated-orcid":true,"given":"Alita A.","family":"Miller","sequence":"first","affiliation":[{"name":"Entasis Therapeutics , 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-6146","authenticated-orcid":true,"given":"Adam B.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"McLeod","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Carter","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir H.","family":"Moussa","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-7422","authenticated-orcid":true,"given":"Ruben","family":"Tommasi","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"2026090313170982300_cit1","unstructured":"Antibiotic Resistance Threats in the United States (2019) Center for Disease Control and Prevention, Washington,\nDC. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"2026090313170982300_cit2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract\ninfection syndromes: occurrence, recurrence, bacteriology, risk factors,\nand disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect. Dis. Clin. North\nAm."},{"key":"2026090313170982300_cit3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrurol.2015.199","article-title":"The emerging threat\nof multidrug-resistant Gram-negative bacteria in urology","volume":"12","author":"Zowawi","year":"2015","journal-title":"Nat. Rev. Urol."},{"issue":"69","key":"2026090313170982300_cit4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"The Infectious\nDiseases Society of America\u2019s 10 x \u201920 Initiative (10\nNew Systemic Antibacterial Agents US Food and Drug Administration\nApproved by 2020): Is 20 x \u201920 a Possibility?","volume":"69","author":"Talbot","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"2026090313170982300_cit5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-Avibactam:\nA Review in the Treatment of Serious Gram-Negative Bacterial Infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"2026090313170982300_cit6","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline,\na newly approved fluorocycline","volume":"38","author":"Lee","year":"2019","journal-title":"Eur. J. Clin.\nMicrobiol. Infect. Dis."},{"key":"2026090313170982300_cit7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/cid\/ciz640","article-title":"Plazomicin: A New Aminoglycoside","volume":"70","author":"Saravolatz","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"2026090313170982300_cit8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-Relebactam\nand Meropenem-Vaborbactam: Two Novel Carbapenem-\u03b2-Lactamase\nInhibitor Combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"2026090313170982300_cit9","doi-asserted-by":"publisher","first-page":"S519","DOI":"10.1093\/cid\/ciz823","article-title":"Cefiderocol:\nA Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens","volume":"69","author":"Bonomo","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"2026090313170982300_cit10","doi-asserted-by":"publisher","first-page":"ofw281","DOI":"10.1093\/ofid\/ofw281","article-title":"The Increase\nin Hospitalizations for Urinary Tract Infections and the Associated\nCosts in the United States, 1998\u20132011","volume":"4","author":"Simmering","year":"2017","journal-title":"Open forum Infect. Dis."},{"key":"2026090313170982300_cit11","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1128\/AAC.00826-13","article-title":"New \u03b2-lactamase inhibitors:\na therapeutic renaissance in an MDR world","volume":"58","author":"Drawz","year":"2014","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090313170982300_cit12","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactams and \u03b2-Lactamase Inhibitors: An\nOverview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"2026090313170982300_cit13","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations\nin the Occurrence of Resistance Phenotypes\nand Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years\nof the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect. Dis"},{"key":"2026090313170982300_cit14","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The Epidemiology of Carbapenem-Resistant Enterobacteriaceae:\nThe Impact and Evolution of a Global Menace","volume":"215","author":"Logan","year":"2017","journal-title":"J. Infect. Dis."},{"key":"2026090313170982300_cit15","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/j.ijantimicag.2007.07.037","article-title":"The clinical\ndevelopment and launch of amoxicillin\/clavulanate for the treatment\nof a range of community-acquired infections","volume":"30","author":"Ball","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2026090313170982300_cit16","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c00579","article-title":"Discovery of ETX0282, an Orally\nAvailable Diazabicycloocta(no)ne\nInhibitor of Class A, C and D Serine \u03b2-lactamases","author":"Durand-Re\u0301ville","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026090313170982300_cit17","unstructured":"CLSI.\n           (2018)  M100: Performance Standards for Antimicrobial\nSusceptibility Testing, 28th ed., Clinical Laboratory Standards Institute, Wayne, PA."},{"key":"2026090313170982300_cit18","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00019","article-title":"Pharmacokinetic\/Pharmacodynamic Determination and Preclinical\nPharmacokinetics of the Novel Beta-lactamase Inhibitor ETX1317 and\nIts Orally Available Prodrug ETX0282","author":"O\u2019Donnell","year":"2020","journal-title":"ACS Infect.\nDis."},{"key":"2026090313170982300_cit19","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as\na serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam\n\u2018enhancer\u2019","volume":"70","author":"Morinaka","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313170982300_cit20","doi-asserted-by":"publisher","first-page":"e02529-16","DOI":"10.1128\/AAC.02529-16","article-title":"WCK 5107 (Zidebactam)\nand WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent \u201c\u03b2-Lactam\nEnhancer\u201d Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-\u03b2-Lactamase-Producing\nHigh-Risk Clones","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313170982300_cit21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/jac\/dkz414","article-title":"Efficacy of human-simulated bronchopulmonary\nexposures of cefepime, zidebactam and the combination (WCK 5222) against\nMDR Pseudomonas aeruginosa in a neutropenic murine\npneumonia model","volume":"75","author":"Kidd","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313170982300_cit22","doi-asserted-by":"publisher","first-page":"16169","DOI":"10.1073\/pnas.1311066110","article-title":"Bacterial cytological\nprofiling rapidly identifies the cellular pathways targeted by antibacterial\nmolecules","volume":"110","author":"Nonejuie","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090313170982300_cit23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0378-1119(95)00584-1","article-title":"Four new\nderivatives of the broad-host-range cloning vector pBBR1MCS, carrying\ndifferent antibiotic-resistance cassettes","volume":"166","author":"Kovach","year":"1995","journal-title":"Gene"},{"key":"2026090313170982300_cit24","doi-asserted-by":"publisher","first-page":"e02072-18","DOI":"10.1128\/JCM.02072-18","article-title":"Don\u2019t\nGet Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa","volume":"57","author":"Van","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"2026090313170982300_cit25","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum\n\u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative\nbacteria including Acinetobacter baumannii","volume":"2","author":"Durand-Reville","year":"2017","journal-title":"Nat.Microbiol."},{"key":"2026090313170982300_cit26","unstructured":"CLSI.\n           (2018)  M07: Methods for Dilution Antimicrobial\nSusceptibility Tests for Bacteria That Grow Aerobically, 11th ed., Clinical and Laboratory Standards\nInstitute, Wayne, PA."},{"key":"2026090313170982300_cit27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1006\/abio.1976.9999","article-title":"A rapid\nand sensitive method for the quantitation of microgram quantities\nof protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."}],"container-title":["ACS Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsinfecdis.0c00020","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/6\/6\/1389\/67303624\/acsinfecdis.0c00020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/6\/6\/1389\/67303624\/acsinfecdis.0c00020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:17:17Z","timestamp":1788455837000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article\/6\/6\/1389\/607855\/In-Vitro-Characterization-of-ETX1317-a-Broad"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2020,6,12]]}},"URL":"https:\/\/doi.org\/10.1021\/acsinfecdis.0c00020","relation":{},"ISSN":["2373-8227"],"issn-type":[{"value":"2373-8227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]}}}